CytoSorbents

CytoSorbents CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification t

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. CytoSorbents is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorbents has multiple active, clinical trials ongoing, including two pivotal randomized, controlled trials in the United States designed to support eventual FDA marketing approval for antithrombotic removal during cardiothoracic surgery using the DrugSorb™-ATR Antithrombotic Removal System.

45th ISICEM | Brussels, Belgium | March 17–20, 2026Critical care is evolving - be part of the conversation at the Intern...
02/02/2026

45th ISICEM | Brussels, Belgium | March 17–20, 2026

Critical care is evolving - be part of the conversation at the International Symposium on Intensive Care and Emergency Medicine in Brussels.

CytoSorbents invites you to a dedicated Symposium - Save the Date:

📅 Thursday, 19 March 2026
⏰ 12:30–13:30
📍 Copper Hall | SQUARE – Brussels Convention Centre

Beyond the symposium, meet the CytoSorbents team in the Silver Foyer throughout the congress and exchange ideas on innovations shaping intensive care worldwide.

Join us in Brussels - let’s move critical care forward, together.

Full program: https://cytosorbents.com/event/45-isicem/

Auf der diesjährigen Jahrestagung der   - der Deutschen Gesellschaft für Thorax-, Herz- und Gefäßchirurgie - in Köln wir...
01/28/2026

Auf der diesjährigen Jahrestagung der - der Deutschen Gesellschaft für Thorax-, Herz- und Gefäßchirurgie - in Köln wird neue klinische Erkenntnisse zur perioperativen präsentieren.

Unser Lunch-Symposium am 21. Februar, 13:45-14:45 Uhr, Raum Sektion 1, Level 0 bringt international anerkannte Experten zusammen, um drei zentrale Herausforderungen in der zu beleuchten:

- Verbesserung der Langzeitergebnisse nach Herztransplantation
- Erweiterung therapeutischer Ansätze beim kardiogenen Schock
- Reduktion des Risikos einer CSA-AKI bei komplexen Eingriffen

Diese Sitzung, unter dem Vorsitz von Prof. Jan Schmitto und Prof. Andreas Zuckermann, bietet evidenzbasierte Perspektiven sowie zukunftsorientierte Konzepte für die klinische Praxis.

Wir freuen uns auf einen anregenden wissenschaftlichen Austausch.

Programm und Link zur Anmeldung: https://cytosorbents.com/event/dgthg-2026/

Morgen ist es soweit:Die nächste Folge unserer Webinarreihe „Medizincontrolling: Wissen kompakt“ steht bevor. Wir widmen...
01/27/2026

Morgen ist es soweit:

Die nächste Folge unserer Webinarreihe „Medizincontrolling: Wissen kompakt“ steht bevor.

Wir widmen uns diesmal dem zentralen Thema der evidenzbasierten Medizin und ihrer Bedeutung für Nutzenbewertung und Erstattungsfähigkeit im Kontext des SGB V – ergänzt durch praxisnahe Fallbeispiele zur Hämoadsorption.

Alle Details und den Link zur Anmeldung finden Sie hier:
👉 https://cyto.news/medcon/jan2026

Ein praxisnaher Start in das Medizincontrolling-Jahr 2026Am 28. Januar 2026 erwartet Sie eine neue Ausgabe unserer Webin...
01/19/2026

Ein praxisnaher Start in das Medizincontrolling-Jahr 2026

Am 28. Januar 2026 erwartet Sie eine neue Ausgabe unserer Webinar-Serie „Medizincontrolling: Wissen kompakt“ – dieses Mal mit einem besonderen Schwerpunkt auf realen Fallbeispielen aus dem klinischen Alltag.

„Abrechnungsprüfung: Der juristische Ernstfall“

Mit Beiträgen von
Dr. iur. Christian Rybak, Franziska Preissing und Dr. med. Volker Humbert.

Ein wertvoller Wissensimpuls für Krankenhausleitungen, Medizincontrolling, Kodierung und Fachabteilungen.

Programm und Link zur Anmeldung: 👉 https://cyto.news/medcon/jan2026

01/13/2026

📌 CytoSorb Case Report:
A young teenager arrived with severe leg pain after a recent flu infection. Within hours, his condition worsened into septic shock — mottled skin, breathing difficulty, falling heart function, and evidence of massive muscle breakdown. Blood tests showed extreme myoglobin levels, overwhelming his kidneys.

Despite fluids, antibiotics, and full critical-care support, the muscle toxins continued to rise. The team initiated continuous kidney support therapy and added CytoSorb hemoadsorption to help remove myoglobin. They monitored blood before and after the adsorber every few hours, allowing precise timing for cartridge changes.

Over the next two days, myoglobin finally began to fall. As kidney support continued and inflammation eased, organ function recovered. After several weeks in intensive care, he regained strength. Six months later, he returned to school with full kidney recovery — a reminder of the resilience of young patients and the value of well-timed supportive therapies.
👉 CytoSorb® — helping clinicians manage critical bleeding risks when time cannot wait.
📑 Full case: https://cytosorbents.com/lit-db/infoitem/11738__2025-11-21__gier-t

DGTHG 2026 - Besuchen Sie uns auf der 55. Jahrestagung der Deutschen Gesellschaft für Thorax-, Herz- und Gefäßchirurgie ...
01/12/2026

DGTHG 2026 - Besuchen Sie uns auf der 55. Jahrestagung der Deutschen Gesellschaft für Thorax-, Herz- und Gefäßchirurgie in Köln!

Save the Date:
Samstag, 21. Februar 2026
13:45 - 14:45 Uhr

Lunch-Symposium zum Thema „Hemoadsorption in cardiac surgery – New insights“ mit:

Prof. Endre Németh (Budapest): Longterm outcome in heart transplant patients after hemoadsorption

Prof. Federico Pappalardo (Catania): Thinking out of the box – CytoSorb in cardiogenic shock patients

Prof. Matthias Thielmann (Essen): Do we have new tools to reduce CSA-AKI?

Vorsitz: Prof. Jan Schmitto (Hannover) und Prof. Andreas Zuckermann (Wien)

Wir freuen uns darauf, Sie in Köln begrüßen zu dürfen - besuchen Sie uns auch an unserem Stand!

🎗️ “A weapon of war became a weapon against cancer.”WWII soldiers exposed to mustard gas had destroyed white blood cells...
01/09/2026

🎗️ “A weapon of war became a weapon against cancer.”

WWII soldiers exposed to mustard gas had destroyed white blood cells. Doctors tested similar compounds against leukemia. Early chemotherapy was toxic, dosing crude, and side effects devastating. Many questioned if the harm outweighed benefit.

Through trials, new drug classes, and careful combinations, chemotherapy was refined. Supportive care reduced toxicity. Gradually, it became central to cancer care.

From weapon to therapy, chemotherapy shows how evidence and practice tame even the harshest beginnings.

•Breakthroughs may start crude and risky.
•Refinement turns them into standards of care.

CytoSorb has followed a similar path-growing stronger with evidence and experience. Read more in our blog ‘Every Innovation Has a Learning Curve’, and visit our Literature Database and Voices Around the World for real-life evidence and experience with CytoSorb 👉 https://cytosorbents.com/blog/

Medizincontrolling 2026: Sicher durch die AbrechnungsprüfungDie Anforderungen an Kliniken steigen – insbesondere, wenn e...
01/07/2026

Medizincontrolling 2026: Sicher durch die Abrechnungsprüfung

Die Anforderungen an Kliniken steigen – insbesondere, wenn es um rechtssichere Abrechnungsprozesse und fundierte Dokumentation geht.

Unsere nächste Session der Reihe „Medizincontrolling: Wissen kompakt“ am 28. Januar 2026, 15:00–16:00 Uhr, widmet sich daher einem zentralen Thema:

Abrechnungsprüfung: Der juristische Ernstfall
Referenten:
- Dr. iur. Christian Rybak, Greenberg Traurig Germany LLP
- Franziska Preissing, CytoSorbents Europe GmbH
- Dr. med. Volker Humbert, CytoSorbents Europe GmbH

Ein kompakter Überblick für alle, die Abrechnungs- und Medizincontrolling aktiv gestalten.

🎆 Goodbye 2025 – Hello 2026! 🎆As the year draws to a close, we take a moment to pause, reflect, and look ahead. 2025 was...
12/31/2025

🎆 Goodbye 2025 – Hello 2026! 🎆
As the year draws to a close, we take a moment to pause, reflect, and look ahead. 2025 was filled with challenges, growth, and countless moments of collaboration and inspiration.

To everyone who walked this path with us — thank you.
Let’s welcome 2026 with curiosity, courage, and hope for all that lies ahead.

✨ Wishing you a joyful New Year’s Eve and a bright, healthy, and peaceful start to the new year! ✨

🎄✨ Day 24: Happy Holidays! ✨🎄As we open the last door of our Advent Calendar, we wish you and your loved ones a holiday ...
12/24/2025

🎄✨ Day 24: Happy Holidays! ✨🎄

As we open the last door of our Advent Calendar, we wish you and your loved ones a holiday season filled with warmth, joy, and togetherness. Thank you for being part of our community this year! Here’s to a wonderful holiday and a bright year ahead!
🎉🎁 https://cyto.news/adventcalendar

Address

305 College Road East
Princeton, NJ
08540

Alerts

Be the first to know and let us send you an email when CytoSorbents posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to CytoSorbents:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram